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Background: Pediatric LRTI hospitalizations are a significant burden on patients, families, and healthcare systems.
This study determined the burden of pediatric LRTIs on hospital settings in British Columbia and the benefits of
prevention strategies as they relate to healthcare resource demand.
Methods: LRTI inpatient episodes for patients <19 years of age during 2008–2010 were extracted from the BC
Discharge Abstract Database. The annual number of acute care beds required to treat pediatric LRTIs was estimated.
Sub-analyses determined the burden due to infants <1 year of age and high-risk infants. Population projections
were used to forecast LRTI hospitalizations and the effectiveness of public health initiatives to reduce the incidence
of LRTIs to 2020 and 2030.
Results: During 2008–2010, LRTI as the primary diagnosis accounted for 32.0 and 75.9% hospitalizations for diseases
of the respiratory system in children <19 years of age and infants <1 year of age, respectively. Infants <1 year of
age accounted for 47 and 77% hospitalizations due to pediatric LRTIs and pediatric LRTI hospitalizations specifically
due to respiratory syncytial virus (RSV), respectively. The average length of stay was 3.1 days for otherwise healthy
infants <1 year of age and 9.1 days for high-risk infants (P <0.0001). 73.1% pediatric LRTI hospitalizations occurred
between November and April. Over the study timeframe, 19.6 acute care beds were required on average to care for
pediatric LRTIs which increased to 64.0 beds at the peak of LRTI hospitalizations. Increases in LRTI bed-days of 5.5
and 16.2% among <19 year olds by 2020 and 2030, respectively, were predicted. Implementation of appropriate
prevention strategies could cause 307 and 338 less LRTI hospitalizations in <19 year olds in 2020 and 2030,
respectively.
Conclusion: Pediatric LRTI hospitalizations require significant use of acute care infrastructure particularly between
November and April. Population projections show the burden may increase in the next 20 years, but
implementation of effective public health prevention strategies may contribute to reducing the acute care demand
and to supporting efforts for overall pediatric healthcare sustainability.
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Lower respiratory tract infections (LRTIs) in children
and infants are common and can require hospitalization;
thus, they are a major public health concern. A number
of viruses including respiratory syncytial virus (RSV), in-
fluenza viruses, parainfluenza viruses, rhinovirus, and
adenovirus are responsible for LRTIs. In children and
infants, RSV is the most common cause; during the first
year of life 50%–70% of children will have an RSV infec-
tion, and by the third year of age almost all children will
have been infected.1
Neonatal and pediatric LRTIs and RSV are often mild,
but can be associated with significant health resource
utilization and result in an important burden on the
patients, families, infrastructure, and budget of public
healthcare systems [1]. Economic analyses indicate that
substantial costs are associated with outpatient physician
office and emergency department visits, but that a ma-
jority of the financial burden is accounted for by costs in
inpatient hospital settings [2,3]. LRTI and RSV/LRTI
hospitalization rates for all children <2 years of age vary
between 0.5% and 2% [4]. In comparison, LRTI, and par-
ticularly RSV specific LRTI, hospitalization rates and
lengths of stay in infants and high-risk infants are sub-
stantially increased and associated with additional costs
[3,4]. High-risk infants include early and late-preterm
infants and those with bronchopulmonary dysplasia and
congenital heart disease [3,5].
In Canada, the annual cost of RSV-associated illness is
over $18 million, and inpatient services associated with
RSV/LRTI hospitalizations account for 62% of these an-
nual expenditures [2]. Over the past two decades, the
impact of LRTI hospitalizations on Canadian health re-
source utilization has increased as the incidences of
admissions have risen from approximately 6,200 to
12,000 hospitalizations per year in children <2 years of
age [2,6,7]. In addition, there is a pronounced seasonal
variation in the incidence of LRTIs. This is likely due to
the RSV season which is defined by the timing of the
onset and offset of increased RSV circulation in a com-
munity. In northern hemisphere countries, the RSV sea-
son usually runs from December through April and is
associated with significantly increased pediatric admis-
sions for LRTIs [8].
The burden of disease associated with LRTIs may be
reduced by effective public health prevention strategies
that decrease hospitalizations and reduce lengths of stay
[4]. Indeed, epidemics such as the most recent H1N1
outbreak led to rapid and important health prevention
and public health initiatives to try to reduce the risk of
transmission and health morbidity [9,10]. Although the
effectiveness of such public health awareness campaigns
are difficult to ascertain, any strategies that can decrease
the incidence of severe viral respiratory infections areexpected to have a considerable and important impact
on acute care settings.
To date there is limited information describing the
burden of pediatric LRTIs and the impact of public
health prevention strategies directed against the infec-
tions causing LRTIs on hospital settings. In large coun-
tries such as Canada, reducing the present and projected
burden of LRTIs and RSV on the public healthcare sys-
tem involves detailed evaluations of the impact of these
diseases on acute care in defined regions. In Canada, it
is likely that identification of the burden of a disease in a
specific province will enable the development of effective
public health initiatives to reduce the incidence of the
disease in this province. The experience in one province
may serve as a model for provinces and territories
throughout the rest of the country. Accordingly, the goal
of these analyses was to determine the burden of
pediatric LRTIs on hospital settings in British Columbia
and to identify the benefits of prevention strategies as
they relate to healthcare resource demand.
Methods
The objectives of the study were to describe the overall
burden and inpatient resources required to care for
pediatric LRTI hospitalizations in British Columbia from
April 2008 to March 2010. The patient and hospital bur-
den as it relates to the length of stay in hospital and the
differences between pediatric sub populations including
those <1 year of age and those defined as high-risk were
determined. Population estimates in British Columbia
for 2008–2010 and projections to 2020 and 2030 were
used to model the projected demand for pediatric LRTI
hospitalizations up to 2020 and 2030. In addition, quan-
titative estimates of the effects of non-pharmacological
interventions to decrease the incidence of LRTIs were
generated to assess how the impact of effective public
health prevention strategies relate to decreased demand
on hospital settings in this province.
The pediatric population was defined as children
younger than 19 years of age at the time of hospital
admission [11,12]. Pediatric population estimates for
2008–2010 and growth statistics were obtained from
BC STATS [13]. BC STATS is the official source for popu-
lation figures within British Columbia health authorities.
The analyses were based on the PEOPLE 35 [13] release
which contains population counts by year, gender, local
health area, and individual year of age. Data projecting
pediatric population growth for 2020 and 2030 were
obtained from the BC STATS component/cohort-
survival model [13].
Hospital discharge records with an International
Classification of Diseases, Tenth Revision (ICD-10) code
identifiable as LRTI as primary diagnosis during the
2008–2009 (n=2498) and 2009–2010 (n=2090) fiscal
Table 1 International Classification of Diseases, Tenth





J10.1 Influenza due to other influenza virus with
J10.81 Influenza gastroenteritis
J10.89 Influenza due to other influenza virus with
J12.0 Adenoviral pneumonia
J12.1 Respiratory syncytial virus pneumonia
J12.2 Parainfluenza virus pneumonia
J12.3 Pneumonia due to SARS-associated coronavirus
J12.8 Other viral pneumonia
J12.81 Pneumonia due to SARS-associated coronavirus
J12.89 Other viral pneumonia
J12.9 Viral pneumonia, unspecified
J13.0 Pneumonia due to Streptococcus pneumoniae
J14.0 Pneumonia due to Hemophilus influenzae
J15.0 Pneumonia due to Klebsiella pneumoniae
J15.1 Pneumonia due to Pseudomonas
J15.20 Pneumonia due to staphylococcus, unspecified
J15.21 Pneumonia due to Staphylococcus aureus
J15.29 Pneumonia due to other staphylococcus
J15.3 Pneumonia due to streptococcus, group B
J15.4 Pneumonia due to other streptococci
J15.5 Pneumonia due to Escherichia coli
J15.6 Pneumonia due to other aerobic Gram-negative bacteria
J15.7 Pneumonia due to Mycoplasma pneumoniae
J15.8 Pneumonia due to other specified bacteria
J15.9 Unspecified bacterial pneumonia
J16.0 Chlamydial pneumonia
J16.8 Pneumonia due to other specified infectious organisms
J17.0 Pneumonia in diseases classified elsewhere
J18.0 Bronchopneumonia, unspecified organism
J18.1 Lobar pneumonia, unspecified organism
J18.2 Hypostatic pneumonia, unspecified organism
J18.8 Other pneumonia, unspecified organism
J20.0 Acute bronchitis due to Mycoplasma pneumoniae
J20.1 Acute bronchitis due to Hemophilus influenzae
J20.2 Acute bronchitis due to streptococcus
J20.3 Acute bronchitis due to coxsackie virus
J20.4 Acute bronchitis due to parainfluenza virus
J20.5 Acute bronchitis due to respiratory syncytial virus
J20.6 Acute bronchitis due to rhinovirus
J20.7 Acute bronchitis due to echovirus
J20.8 Acute bronchitis due to other specified organisms
J20.9 Acute bronchitis, unspecified
Table 1 International Classification of Diseases, Tenth
Revision (ICD-10) codes identifying for lower respiratory
tract infections (Continued)
J18.9 Pneumonia, unspecified organism
J21.0 Acute bronchiolitis due to respiratory syncytial virus
J21.1 Acute bronchiolitis due to human metapneumovirus
J21.8 Acute bronchiolitis due to other specified organisms
J21.9 Acute bronchiolitis, unspecified
J22.0 Unspecified acute lower respiratory infection
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associated to pediatric patients from any acute care hos-
pital in British Columbia were obtained from the Canadian
Institute for Health Information (CIHI) Discharge Ab-
stract Database (DAD) [14]. Codes to identify an ad-
mission due to an LRTI are shown in Table 1 [15].
The DAD contains data on facility discharges across
Canada including demographic, administrative, and
clinical data for hospital discharges (inpatient acute,
chronic, and rehabilitation) and day surgery interven-
tions. Co-morbidities and other conditions were derived
from ICD-10 diagnosis codes specified in any of the
first 10 diagnosis fields in the DAD published population.
Data for this project was provided by the Fraser Health
Authority (FHA). Access to the data was approved by
FHA’s research office. An ethics approval exemption was
granted on the basis of the study using unidentifiable non-
clinical/administrative data at an aggregate level for pur-
poses of reviewing workload and resource utilization and
planning capacity into the future.
Data were examined by patients’ age, sex, hospital of
admission, local health areas of residence, and admission
date. Hospital length of stay (LOS) and accompanying
diagnoses listed with the LRTI hospitalization were
described. LOS was obtained directly from the DAD’s
calculated LOS field, which is a derived variable. For
inpatient abstracts, LOS is the difference in days between
the admission date and discharge date. If the difference
was 0 (i.e., admission date equals discharge date), the
calculated LOS was 1. LOS was described for all pediatric
patients, infants <1 year of age at the time of hospital ad-
mission, as well as for infants at high risk for an LRTI
hospitalization. High-risk infants were defined according
to the ICD-10 codes for congenital heart disease, broncho-
pulmonary dysplasia, congenital lung disease, and preterm
birth defined as <37 weeks completed gestation [5,15,16]
(Table 2).
Average annual hospitalization rates for LRTI among
the pediatric population were calculated. The overall
hospitalization rates (per 100,000 children) were deter-
mined using the total number of LRTI hospitalizations
and BC STATS PEOPLE 35 population estimates. Results
are described as the number of hospital bed days used,
Table 2 International Classification of Diseases, Tenth




Pre-term P07.2 Extreme immaturity of newborn
P07.3 Other preterm newborn
CHD Q20 Congenital malformations of cardiac chambers
and connections (select subcategories)
Q20.0 Common arterial trunk
Q20.1 Double outlet right ventricle
Q20.2 Double outlet left ventricle
Q20.3 Discordant ventriculoarterial connection
Q20.4 Double inlet ventricle
Q20.5 Discordant atrioventricular connection
Q20.6 Isomerism of atrial appendages
Q21 Congenital malformations of cardiac septa
(select subcategories)
Q21.0 Ventricular septal defect
Q21.1 Atrial septal defect
Q21.2 Atrioventricular septal defect
Q21.3 Tetralogy of Fallot
Q21.4 Aortopulmonary septal defect
Q21.8 Other congenital malformations of cardiac septa
Q22 Congenital malformations of pulmonary
and tricuspid valves (all subcategories)
Q23 Congenital malformations of aortic and mitral
valves (all subcategories)
Q24 Other congenital malformations of heart
(all subcategories)
Q25 Congenital malformations of great arteries
(select subcategories)
Q25.0 Patent ductus arteriosus
Q25.1 Coarctation of aorta
Q25.2 Atresia of aorta
Q25.3 Stenosis of aorta
Q25.4 Other congenital malformations of aorta
Q25.5 Atresia of pulmonary artery
Q25.6 Stenosis of pulmonary artery
Q25.7 Other congenital malformations of pulmonary
artery
Q26 Congenital malformations of great veins
(all subcategories)
BPD P27.1 Bronchopulmonary dysplasia originating in
the perinatal period
CLD Q33 Congenital malformations of lung
(all subcategories)
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average number of beds required full time to care for
LRTI patients during the study period of 2008 to 2010.
The projected increases in acute care beds and bed
days for LRTI hospitalizations in 2020 and 2030 were cal-
culated based on rates for 2008–2010 and population
growth statistics provided by BC STATS. The best possible
estimates of the effectiveness of public health initiatives
to reduce the incidence of LRTI in 2020 and 2030 were
estimated from a targeted literature review which ana-
lyzed the effects of non-pharmacological interventions
on hospitalizations for severe viral respiratory disease.
Based on this review, the most reasonable and appropriate
benefit described as a decrease in the incidence of severe
LRTI disease was applied to show the impact it would
have on hospital days and beds needed in 2020 and 2030.
Statistical analysis
All statistical analyses were performed with the use of
MedCalc software, version 12.1.1 [17]. A MS Access
2007 database containing all inpatient records was used
to store, manipulate, filter, and summarize the data. MS
Excel 2007 was used for basic computations and to pre-
pare charts.
Hospitalizations accounted for the total bed-days; the
average number of beds was defined as total bed-days
divided by the number of days in the period under ana-
lysis; average LOS was estimated as total bed-days divided
by the number of hospitalizations; and the peak in bed
occupancy was defined as the maximum number of beds
occupied simultaneously.
Rates were calculated using the best population esti-
mates available and the number of hospitalizations for
corresponding groups defined by the patients’ primary
diagnosis, age, and region of residence. The confidence
intervals for these rates were calculated using the normal
approximation method. Chi-square tests were used for
rate comparisons, with Yates’ correction for continuity.
Results
All children (<19 years of age)
In British Columbia during 2008–2010, diseases of the
respiratory system (ICD-10 Chapter X) accounted for
14326/186609 (7.7%) primary hospital diagnoses among
all children <19 years of age. Hospitalizations for LRTI
as the primary diagnosis occurred in 4588/14326 (32.0%)
of all respiratory admissions in children <19 years of age.
The average LOS in hospital for LRTI as the primary
diagnosis was 3.10 days (95% confidence interval [CI]
3.03–3.21; 82% within 5 days); this is equivalent to a yearly
average of 19.6 acute beds required to treat pediatric
LRTIs (Table 3).
Most of the LRTI admissions were for an unspecified
viral cause (2932/4588; 63.9%). Pneumonia, organism
Table 3 Pediatric hospitalizations for lower respiratory
tract infection as primary diagnosis, 2008–2010




All children 4588 14319 3.10 (3.03–3.21) 19.6 64
Infants <1y 2165 7002 3.23 (3.10–3.37) 9.6 41
Bed days are for separations within both fiscal years (length of stay of cases
discharged).
Average beds calculated at 100% utilization (equivalent to average across year).
Maximum beds correspond to peak in daily bed utilization.
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listed LRTI as the primary diagnosis (1215/4588; 26.5%)
with acute bronchiolitis due to RSV (ICD-10 code J21.0;
1198/4588; 26.1 %); acute bronchiolitis, unspecified
(ICD-10 code J21.9; 854/4588; 18.6%); bronchopneumo-
nia, unspecified organism (ICD-10 code J18.0; 354/4588;
7.7%); and viral pneumonia unspecified (ICD-10 code
J12.9; 138/4588; 3%) also among the top 5 diagnoses.
RSV-specific infections accounted for 1353 (29.5%)
cases of LRTI as the primary diagnosis among all chil-
dren <19 years of age. Most RSV-associated hospitaliza-
tions were for acute bronchiolitis due to RSV accounting
for 1198 (86%) RSV-associated hospitalizations, followed
by RSV pneumonia (ICD-10 code J12.1; 115 cases; 8.5%),
and acute bronchitis due to RSV (ICD-10 code J20.5;
40 cases; 3%).
Infants (<1 year of age)
During 2008–2010, diseases of the respiratory system
accounted for 2853/102972 (2.8%) primary diagnoses
among infants <1 year of age (including deliveries/births).
Hospitalizations for LRTI as the primary diagnosis oc-
curred in 2165 (75.9%) infants <1 year of age. The aver-
age LOS for LRTI as the primary diagnosis was 3.23 days
(95% CI 3.10–3.37; 79.5% within 5 days); this translates
to a yearly average of 9.6 beds per day needed to treat
LRTIs in infants <1 year of age (Table 3).
RSV-specific infections accounted for 1042 (48.1%)
cases of LRTI as the primary diagnosis among infants
<1 year of age. Most RSV-associated hospitalizations
were for acute bronchiolitis due to RSV accounting for
961 (92.2%) RSV-associated hospitalizations, followed by
RSV pneumonia (52 cases; 5%), and acute bronchitis due
to RSV (29 cases; 2.8%).
Acute bronchiolitis due to RSV was the most frequently
listed LRTI as the primary diagnosis (961/2165; 44.4%)
followed by acute bronchiolitis, unspecified (575/2165;
26.6 %); pneumonia, unspecified organism (194/2165;
9%); bronchopneumonia, unspecified organism (102/2165;
4.7%); and acute bronchiolitis due to other specified
organisms (ICD-10 code J21.8; 51/2165; 2.4%).
Infants <1 year of age accounted for 47 and 77% of
LRTI and RSV-specific LRTI hospitalizations, respect-
ively, among all children (Figure 1). Hospitalization ratesfor LRTI as the primary diagnosis among infants <1 year
of age were significantly increased compared to children
1–<19 years of age (2410/100,000 population <1 year of
age vs. 235/100,000 children 1–<19 years of age;
P <0.0001). Bed-days rates for LRTI as the primary diag-
nosis were significantly increased among infants <1 year
of age compared to children 1–<19 years of age (15,663/
100,000 population <1year of age vs. 1473/100,000
children 1–<19 years of age; P <0.0001). Considering
the bed days spent by those patients, this is an equivalent
bed rate of 21.45 beds/100,000 infants <1 year of age
per day and 2.02 beds/100,000 children 1–<19 years of
age per day (P <0.0001).
Infants at risk
At-risk infants accounted for 1.8% (40/2165) of LRTI
hospitalizations in all infants <1 year of age. The average
LOS among at-risk infants was significantly longer com-
pared to other pediatric patients (9.1 days, vs. 3.10 days,
respectively P <0.0001) (Table 4).
Seasonal and regional variations
Most LRTI hospitalizations among all children <19 years
of age (LRTI, 73.1%; RSV, 88.1%) and infants <1 year
of age (LRTI, 79.1%; RSV, 88.4%) occurred between
November and April (Figure 2). Bed occupancy was
highest in January and February of 2009 and March of
2010 with peaks of 53 beds among all children <19 years
of age and 40 beds among infants <1 year of age in January
and February 2009, respectively, and 64 beds among all
children <19 years of age and 41 beds among infants
<1 year of age in March 2010. Regionally, LRTI hos-
pitalization rates among all children <19 years of age
and infants <1 year of age in the Interior, Northern
BC, and Vancouver Island were higher than the average
provincial rate and significantly lower in British Columbia’s
lower mainland (Table 5).
Projected LRTI hospitalizations for 2020 and 2030
Population projections estimated a 6.6% growth in the
pediatric population by 2020 and 17.2% growth by 2030
(Table 6). Assuming the same incidence of LRTI hospita-
lizations required by pediatric patients, these projections
predicted a growth in LRTI bed-days of 5.5% among
all children <19 years of age and 16.3% among infants
<1 year of age by 2020 and 16.2% among all children
<19 years of age and 14.9% among infants <1 year of
age by 2030. In 2020, the average number of acute care
beds required to treat pediatric LRTIs will be 20.7 among
all children 0–<19 years of age including 11.2 among the
subpopulation of infants <1 year of age. This will increase
to a maximum bed occupancy of 68 among all children
including 48 in infants <1 year of age during the peak
months for LRTI hospitalizations. In 2030, 22.8 acute
Table 4 Hospitalizations and average length of stay
among high-risk compared to otherwise healthy patients,
2008–2010
Infants <1 y Children 1–<19 Total
Risk level Count ALOS (95% CI) Count ALOS (95% CI) Count
High risk 40 9.10 (5.5–12.7) 38 4.3 (0–15.1) 78
Healthy 2125 3.10 (3.0–3.2) 2385 3.0 (2.9–3.1) 4510
ALOS, Average Length of Stay.
The average length of stay (ALOS) among at-risk infants was significantly
longer compared to other pediatric patients (9.1 days, vs. 3.10 days,
respectively P <0.0001).
Figure 1 Pediatric hospitalizations for LRTI and RSV according to age, 2008–1010. A. Pediatric lower respiratory tract infection (LRTI)
hospitalizations. Infants <1 year of age accounted for 47 % of LRTI hospitalizations among all children B. Pediatric respiratory syncytial virus (RSV)
specific hospitalizations. Infants <1 year of age accounted for 77% RSV-specific LRTI hospitalizations among all children.
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age including 11.0 among infants <1 year of age. This will
increase to a maximum bed occupancy of 74 beds among
all children including 47 among infants <1 year of age in
the winter months (Table 7).
Impact of public health prevention strategies on future
LRTI hospitalizations
A targeted literature review quantitating the effect of
non-pharmacological interventions on LRTI hospitaliza-
tions revealed a study that indicated a 12.5% reduction
in hospitalizations may be achieved using hand-washing
as a public health prevention strategy [18]. This reduc-
tion was applied to the projected increase in LRTI
Figure 2 Pediatric hospitalizations for LRTI and RSV according to month and year of discharge, 2008–2010. A. Lower respiratory tract
infection (LRTI) hospitalizations in all children. 73.1% LRTI hospitalizations among all children <19 years of age and 79.1% LRTI hospitalizations
among infants <1 year of age occurred between November and April. B. Respiratory syncytial virus (RSV) specific hospitalizations in all children.
88.1% RSV hospitalizations among all children <19 years of age and 88.4% RSV hospitalizations among infants <1 year of age occurred between
November and April.
Table 5 Hospitalization rates for lower respiratory tract
infection as primary diagnosis by region, 2008–10
Health Authority Infants All children <19
Interior 3049 (2634;3464) * 289 (263;316) *
Fraser 2030 (1821;2239) * 203 (188;217) *
Vancouver Coastal 1790 (1532;2047) * 174 (156;191) *
Vancouver Island 3085 (2661;3509) * 272 (246;299) *
Northern 3626 (3019;4234) * 373 (330;416) *
British Columbia 2410 (2309;2511) 235 (228;241)
Rates are per 100,000 population; 95% CI are shown in parentheses.
Rates for All Children include infants and patients up to 19 years of age.
(*) indicates significant difference (P value < 0.0001) in rates for health
authority vs. provincial average.
Lower respiratory tract infection hospitalization rates among all children <19
years of age and infants <1 year of age in the Interior, Northern BC, and
Vancouver Island were higher than the average provincial rate and
significantly lower in British Columbia’s lower mainland.
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prevention strategy that could replicate these findings in
reducing the prevalence of LRTI admissions, in a sense,
counteracts the effects of population growth. In 2020, a
12.5% decrease in hospitalizations in an anticipated <19
year old British Columbia pediatric population of 1,025,000
could potentially result in 307 less hospitalizations, 963 lessTable 6 British Columbia population estimates and
projections to 2020 and 2030. Population projections
estimated a 6.6% growth in the pediatric population by
2020 and 17.2% growth by 2030
Age Group 2008 2020 2030
Infants <1 44,156 52,032 51,410
All children <19 912,762 973,395 1,069,974
Source: BC Stats PEOPLE 35.
Table 7 Projections for lower respiratory tract infection hospitalizations with and without a public health intervention
strategy
Year(s) Hospitalizations All Children Bed-days All Children Beds All Children
Infants Infants Infants
Actual 2008-10 1,083 2,294 3,501 7,160 9.6 (41) 19.6 (64)
Proj1 2020 1,254 2,409 4,071 7,553 11.2 (48) 20.7 (68)
2030 1,239 2,652 4,022 8,316 11.0 (47) 22.8 (74)
Proj2 2020 1,094 2,102 3,552 6,590 9.7 (41) 18.1 (59)
2030 1,081 2,314 3,509 7,256 9.6 (41) 19.9 (65)
Beds correspond to annual average calculated from bed-days; peak in beds shown in parenthesis.
Proj1=projections based solely on population growth.
Proj2=Proj1 adjusted for public health intervention strategy.
Population projections predicted a growth in lower respiratory tract infection (LRTI) bed-days of 5.5% among all children <19 years of age and 16.3% among
infants <1 year of age by 2020 and 16.2% among all children <19 years of age and 14.9% among infants <1 year of age by 2030. A public health prevention
strategy that reduces LRTI hospitalizations by 12.5% may counteract the effects of population growth.
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LRTIs. A 12.5% decrease in hospitalizations in an antici-
pated <1 year old British Columbia pediatric population of
52,032 could result in 160 less hospitalizations, 519 less
bed-days, and 1.5 less beds. Similarly in 2030, in a pro-
jected <19 year old population of 1,128,585, there could
be 338 less hospitalizations, 1060 less bed-days, and 2.9
less beds required annually to treat LRTIs. In a pro-
jected <1 year old population of 51,410, there could be
158 less hospitalizations, 513 less bed-days, and 1.4 less
beds (Table 7).
Discussion
LRTIs and particularly RSV associated LRTIs account
for a substantial number of pediatric hospitalizations
and utilize an important number of beds. In British
Columbia during 2008–10, LRTI as the primary diagno-
sis accounted for a significant proportion of diseases of
the respiratory system in all children <19 years of age
and the majority of hospitalizations for diseases of the
respiratory system in infants <1 year of age. Infants <1
year of age accounted for 47 and 77% hospitalizations due
to pediatric LRTIs and LRTIs specifically due to RSV, re-
spectively. Acute bronchiolitis due to RSV was the most
frequently listed LRTI as the primary diagnosis in infants
<1 year of age. There was considerable seasonal variation
in the incidence of hospitalizations. Most pediatric hospi-
talizations attributable to LRTIs in British Columbia hos-
pitals occurred between November and April.
These data demonstrate that LRTI and RSV specific
LRTI are a significant disease burden in the pediatric
population in British Columbia, especially in infants
<1 year of age and those at high-risk. Although high-risk
infants do not account for the majority of the number of
pediatric LRTI hospitalizations, their hospital LOS was
three times as long as other pediatric patients. This sug-
gests at-risk infants place a greater demand per patient
on the acute care setting. Previous studies show thelengths of RSV-associated stay in Canada range from
4.6 to 6.7 days for pediatric patients, and from 8.6 to
11.8 days for pediatric patients with diagnoses such as
congenital heart disease, chronic lung disease, immuno-
deficiency, or multiple congenital anomalies, [19] and up
to 14.71 days for preterm infants with probable RSV com-
pared to 5.04 days for term infants [20]. These data are
in accordance with our observations in British Columbia.
Due to the high rate of pediatric hospitalization and
extended lengths of stay, there are significant medical
costs related to LRTI. Previous economic analyses indi-
cate that infants with LRTI have healthcare costs over
$9000 higher in the first year of life than infants without
infection [21]. The LRTI burden on the healthcare sys-
tem in British Columbia is expected to increase in the
next 20 years as estimates of population growth suggest
that the number of acute care beds needed to care for
pediatric LRTI hospitalizations will rise. The study esti-
mated an increase in the pediatric population of approxi-
mately 17% by 2030 which may be a conservative estimate
compared to other published reports which calculate 31%
growth in the population of children 0–19 years of age
in British Columbia from 2010 to 2031 [22]. However,
predictions describing the implementation and evaluation
of effective public health prevention strategies indicate
that such measures can potentially reduce the incidence
of the severe viral infections that are predominant con-
tributors to LRTI hospitalizations and can significantly
contribute to pediatric acute care sustainability. Non-
pharmacological intervention strategies can occur in the
home, and health care practitioners need to educate par-
ents and caregivers about methods that can be used to
prevent children from infections. These include frequent
hand washing which can significantly reduce the rate of
spread of infection from 4.2 to 0.6–1.1% [23] and sepa-
rating infected people from non-infected people, espe-
cially at-risk children [24]. The effectiveness of other
public health initiatives warrants evaluation.
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strategies to infectious diseases was illustrated during
the 2009 H1N1 influenza pandemic. Public opinion polls
demonstrated that 59–67% Americans adopted hand
washing and 35–38% avoided exposure to others with
influenza-like symptoms [10]. While the effectiveness of
such awareness campaigns are difficult to ascertain, strat-
egies that can decrease the prevalence of LRTIs may have
considerable impact on acute care settings especially
during seasonal LRTI and RSV outbreaks. Compliance
with vaccines that are efficacious at reducing the inci-
dence of severe viral respiratory infections [25] or the
use of monoclonal antibodies to reduce the risk of RSV
hospitalization in high-risk infants [26] may also have a
significant contribution to reducing the demand of LRTIs
on pediatric inpatient settings. In some areas, a modified
combination of prevention may be useful. This may be
applicable in British Columbia in the Interior, Northern
BC, and Vancouver Island where LRTI hospitalization
rates among all children <19 years of age and infants
<1 year of age were higher than the average provincial
rate. Furthermore, this study revealed that the primary
diagnosis for LRTIs were predominantly for an unspecified
cause. Improved surveillance on the cause of pediatric
LRTI hospitalizations may provide valuable insight for
assessing current and future demand as well as for devel-
oping targeted prevention strategies.
Our study reflects the impact of LRTIs in a closed
population [14]. This may be an advantage over other
nationwide administrative analyses that only evaluate a
sample of a population. There are however limitations
associated with this study. First, the use of ICD-10 codes
with hospital discharge diagnoses to estimate LRTI hos-
pitalizations may be unsatisfactory as discharge diagnoses
can be miscoded. Second, as previously noted the sensi-
tivity of the use of LRTI ICD-10 codes is uncertain as
most of the LRTI hospitalizations were for an unspecified
viral cause. The study was unable to determine if each
hospitalization had a laboratory investigation to determine
the underlying cause. Third, it is difficult to evaluate the
impact of health prevention strategies in decreasing severe
respiratory disease as the effectiveness of such measures
may only be quantified using the best estimates available
in the literature. Fourth, the future predictions on de-
mand were based on 2008–2010 data only, whereby the
retrospective inclusion of more years would potentially
improve the accuracy of estimating the temporal trend
and demand. Fifth, the study only assessed the inpatient
utilization of pediatrics with a primary LRTI diagnosis,
whereby those with secondary diagnoses, for example
those acquiring nosocomial LRTI, were not included.
Finally, while our findings suggest that LRTIs are a sig-
nificant burden on the healthcare system in British
Columbia and public health prevention strategies canseverely impact this, the generalizability of this data to
other provinces in Canada and other countries is
unknown.
Conclusion
In summary, we present data for all pediatric LRTI
and RSV/LRTI hospitalization occurrences in British
Columbia during 2008–2010. We identified pediatric
LRTIs, and specifically in infants <1 year of age and
at-risk infants, as a significant burden on the acute care
setting in British Columbia, having pronounced seasonal
variability. Population projections suggest that this bur-
den will increase in the next 20 years whereby the imple-
mentation of effective public health prevention strategies
may be an important strategy for pediatric healthcare
sustainability, particularly as it relates to acute care ac-
cess with fixed infrastructure. Information about the risk
of hospitalization in the pediatric population along with
a greater understanding of the factors involved in the
seasonality patterns of LRTI hospitalizations and the eti-
ology for the LRTI hospitalizations may contribute to the
development of algorithms that can identify risk and
allow the development of prevention strategies to be
implemented at specific times of the year. Comprehen-
sive knowledge of the province-specific impact and
cause of pediatric LRTIs can lead to the development
of prevention strategies that if effectively implemented
can ease the burden of disease on patients, health care
infrastructure, and budgets, all of which are important
for healthcare sustainability. The methodology and
analyses used to evaluate the burden of pediatric LRTIs
in British Columbia may serve as a model that can be
extrapolated for use in other Canadian provinces and
countries.
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